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It has recently been reported that light/dark transitions lead to changes in choroidal blood ﬂow. Several observations indicate that
these changes in choroidal perfusion are triggered at least in part by neural mechanisms. In the present study we hypothesised that
the choroidal blood ﬂow response to changes in retinal illumination may be modiﬁed by either the muscarinic receptor antagonist
atropine or by the b-receptor antagonist propranolol. In 15 healthy subjects the response of choroidal perfusion was studied in a
randomised placebo-controlled three way cross-over study using laser Doppler ﬂowmetry and laser interferometric measurement of
fundus pulsation amplitude. Before drug administration a transition from light to dark reduced both choroidal haemodynamic
parameters by 8%–12%. Neither propranolol nor atropine altered basal choroidal blood ﬂow or choroidal blood ﬂow responses to
light/dark transitions. Our data indicate that neither muscarinic nor b-receptors are involved in the choroidal blood ﬂow response to
changes in retinal illumination. Further studies are required to elucidate which mechanisms contribute to this blood ﬂow behaviour
of the choroid.
 2003 Elsevier Ltd. All rights reserved.
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There is recent evidence that the choroid changes its
blood ﬂow during light/dark transitions. Using diﬀerent
techniques it has been shown that choroidal perfusion is
lower in the dark than in light (Fuchsj€ager-Mayrl, Pol-
ska, Malec, & Schmetterer, 2001; Longo, Geiser, &
Riva, 2000). The reason for this behaviour is unknown
and the mechanisms underlying the change in blood
ﬂow remain to be elucidated. The increase in oxygen
consumption during darkness is unlikely to contribute
to the decrease in choroidal perfusion. The concomitant
decrease in outer retina pO2 may potentially lead to a
decrease in choroidal pO2, but the human choroid has
been shown to be insensitive to alterations in arterial* Corresponding author. Address: Department of Clinical Pharma-
cology, University of Vienna, W€ahringer G€urtel 18-20, A-1090 Vienna,
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doi:10.1016/S0042-6989(03)00332-8blood oxygen tension (Geiser et al., 2000; Schmetterer
et al., 1996).
Based on several observations it has been hypothes-
ised that a neural mechanism is underlying the change in
choroidal perfusion rate during light/dark transitions
(Fuchsj€ager-Mayrl et al., 2001; Longo et al., 2000).
Most importantly a unilateral light/dark transition leads
to a decrease in choroidal blood ﬂow in both eyes in-
dicating a neural cross-talk among the eyes (Fuchsj€ager-
Mayrl et al., 2001). Based on these previous experiments
we hypothesised that the choroidal blood ﬂow response
during light/dark transitions may be altered by phar-
macological modiﬁcation of the autonomic nervous
system in healthy subjects. Accordingly, the response of
the choroid was studied during either muscarinic re-
ceptor blockade with atropine or b-receptor blockade
with propranolol. This was based on the hypothesis that
the decrease in choroidal blood ﬂow during light/dark
transitions is either due to withdrawal of cholinergic
vasodilatory tone or due to activation of adrenergic
vasoconstrictor tone. If this hypothesis remains true one
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atropine) or increased vasoconstriction (during propra-
nolol). Choroidal blood ﬂow was assessed with two in-
dependent methods, namely laser Doppler ﬂowmetry
(Geiser, Diermann, & Riva, 1999; Geiser et al., 2000)
and laser interferometric measurement of fundus pul-
sation amplitude (FPA) (Schmetterer, Lexer, Unfried,
Sattmann, & Fercher, 1995).2. Materials and methods
2.1. Subjects
After approval from the Ethics Committee of Vienna
University School of Medicine was obtained, 15 healthy
male non-smoking volunteers were studied (age range:
20–34, mean±SD: 24.5 ± 3.5). The nature of the study
was explained and all subjects gave written consent to
participate. Each subject passed a screening examination
that included medical history and physical examination,
12-lead electrocardiogram, complete blood count, acti-
vated partial thromboplastin time, thrombin time,
ﬁbrinogen, clinical chemistry (sodium, potassium, cre-
atinine, uric acid, glucose, cholesterol, triglycerides,
alanine aminotransferase, aspartate transcarbamylase,
c-glutamyltransferase, alkaline phosphatase, total bi-
lirubin, total protein), hepatitis A, B, C and HIV-
serology, urine analysis, and a urine drug-screen. Subjects
were excluded if any abnormality was found as part of
the pretreatment screening unless the investigators
considered an abnormality to be clinically irrelevant.
Furthermore an ophthalmic examination, including slit
lamp biomicroscopy and indirect funduscopy was per-
formed. Inclusion criteria were normal ophthalmic
ﬁndings and ametropia <3 diopters.
2.2. Study designs
The study followed a randomised double masked,
placebo-controlled three way cross-over design with
propranolol (non-selective b-receptor antagonist), atro-
pine (muscarinic-receptor antagonist) or placebo
(physiological saline solution) on separate study days.
The washout period between study days was at least 4
days. Prior to the study a sample size calculation was
performed. The reproducibility of choroidal blood ﬂow
changes during light/dark transition using laser Doppler
ﬂowmetry was calculated based on the results of our
previous study (Fuchsj€ager-Mayrl et al., 2001). These
data were used for the sample size calculation selecting
an a-level of 0.05 and a b-level of 0.2. A change in
choroidal blood ﬂow in the order of 8% was assumed to
be relevant. This lead to a sample size of 15 subjects.
The dose of propranolol and atropine was based on
previous trials in healthy humans. Propranolol (Ind-eral, Zeneca, Macclesﬁeld, UK) was administered as an
intravenous bolus infusion at a dose of 80 lg/kg, fol-
lowed by a continuous infusion of 1 lg/kg/min over 70
min (De Jonge & Garrel, 1997). Atropine (Atropinsulfat
Lannacher, Lannach, Austria) was infused as an intra-
venous bolus infusion at a dose of 15 lg/kg, followed by
a continuous infusion of 0.15 lg/kg/min over 70 min
(Sch€afers et al., 1997). These doses of atropine and
propranolol were also used for our previous studies in
healthy volunteers investigating mechanisms of retinal
and choroidal blood ﬂow regulation during isometric
exercise (Jandrasits et al., 2001; Polska et al., 2003). Two
syringes ﬁlled with physiological saline solution were
prepared as placebo, which were identical in appearance
with the atropine and the propranolol syringes to
maintain double masked conditions.
In order to ensure constant pupil diameters
throughout the experiments tropicamide was instilled
into the right eye. After full pupil dilatation was
achieved baseline measurements of ocular and systemic
haemodynamics were performed. Subjects were then
kept in room light for 20 min. The room light consisted
of neon lamp illumination with a radiance of approxi-
mately 115 lW/cm2/steradiant. At the end of this 20 min
period baseline measurements of choroidal haemody-
namic parameters were performed again. Thereafter the
room light was turned oﬀ for 20 min. During this period
of darkness the radiance was below 0.5 lW/cm2/stera-
diant. At the end of this 20 min period in darkness oc-
ular haemodynamic parameters were assessed again.
Finally, the light was turned on and subjects were
measured again after 10 min. After completion of this
pre-treatment part of the experiment a resting period of
30 min was scheduled. Ten minutes before the end of
this resting period full pupil dilation was again achieved
by topical administration of tropicamide. Another light/
dark transition period was performed during the last 50
min of drug administration, which was identical to the
pretreatment period. Intraocular pressure was measured
at the begin and the end of each period. Constant pupil
diameters throughout the study period were ensured by
repeated measurement with the slit lamp.
2.3. Methods
Blood pressure and pulse rate. Systolic, diastolic and
mean blood pressures (SBP, DBP and MAP) were mea-
sured on the upper arm by an automated oscillometric
device (HP-CMS patient monitor, Hewlett Packard, Palo
Alto, CA, USA). From these data the pulse pressure
amplitude was calculated as PPA¼ SBP-DBP. Pulse rate
(PR) was automatically recorded from a ﬁnger pulse-
oxymetric device (HP-CMS patient monitor).
Intraocular pressure. A slit-lamp mounted Goldmann
applanation tonometer was used to measure intraocular
pressure (IOP). Before each measurement one drop of
Table 1
Baseline haemodynamic parameters
Day 1 Day 2 Day 3
Mean arterial pressure
(mmHg)
84± 9 83± 10 84± 9
Pulse pressure amplitude
(mmHg)
58± 10 57± 12 56± 9
Pulse rate (beats/min) 69± 8 71± 10 67± 6
FPA (lm) 4.5± 1.5 4.6± 1.5 4.5± 1.3
Choroidal blood ﬂow
(arbitrary units)
19.6± 4.0 20.1± 3.2 20.1± 4.8
Intraocular pressure
(mmHg)
13± 2 14± 2 13± 2
Data are presented as means±SD.
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ﬂuorescein sodium was used for local anaesthesia of the
cornea.
Laser Doppler ﬂowmetry. Subfoveal choroidal blood
ﬂow was performed by laser Doppler ﬂowmetry (Riva,
Cranstoun, Grunwald, & Petrig, 1994). In this tech-
nique, the vascularized tissue is illuminated by coherent
laser light. Light scattered by the moving red blood cells
(RBCs) undergoes a frequency shift. In contrast, static
tissue scatterers do not change the light frequency, but
lead to randomisation of light directions impinging on
RBCs. Hence, RBCs receive light from numerous ran-
dom directions. As the frequency shift is dependent not
only on the velocity of the moving RBC, but also on the
angle between the wave vectors of the incident and the
scattered light, scattering of the light in tissue broadens
the Doppler shift power spectrum. From this spectrum,
the following ﬂow parameters are calculated (Bonner &
Nossal, 1990): mean RBCs velocity in Hz, blood volume
and blood ﬂow (FLOW) in arbitrary units.
In the present study, a compact laser Doppler ﬂow-
meter, which has been described in detail in a previous
paper, was used for the measurements of the choroidal
blood ﬂow parameters (Geiser et al., 1999; Geiser et al.,
2000). The laser beam of a single mode laser diode (785
nm, 90 lW at the cornea) is delivered to the eye via a
confocal optical system. The beam diameter at the
fundus is nominally 12 lm. The light is collected by a
bundle of six ﬁbres with a core diameter of 110 lm,
which are arranged on a circle with a diameter of 180 lm
(indirect detection). All measurements were performed
in the fovea by asking the subject to directly ﬁxate at the
beam, which appeared as a small red dot.
Fundus pulsation measurement. Pulse synchronous
pulsations of the ocular fundus were recorded with a laser
interferometric method (Schmetterer et al., 1995). The
method uses a single mode laser beam with a wavelength
of 780 nm for illumination of the subjects eye. The power
of the laser beam is approximately 80 lW at a beam di-
ameter of 1 mm. The light is reﬂected at the anterior
surface of the cornea and at the fundus. The light from
the front side of the cornea serves as a reference wave.
Due to the high coherence length of the laser light the
interferences produced by the twowaves can be observed.
This permits calculation of the relative distance changes
between cornea and retina during the cardiac cycle. These
distance changes are in the order of several micrometers
and are caused by the rhythmic ﬁlling of ocular vessels
during systole and diastole. The distance between cornea
and retina decreases during systole, because the blood
volume entering the eye via the arteries exceeds the blood
volume leaving the eye via the veins, and increases during
diastole. The maximum distance change between the
cornea and fundus during the cardiac cycle is called FPA,
yielding information on the pulsatile component of oc-
ular blood ﬂow (Schmetterer et al., 1998).2.4. Data analysis
All responses in choroidal haemodynamic parameters
during light/dark transitions were expressed as percent-
age change from baseline values. The eﬀect of atropine
and propranolol on choroidal blood ﬂow changes dur-
ing light/dark transitions were assessed with a repeated
measure ANOVA model. The eﬀect of the light/dark
transition was calculated as the time eﬀect. The eﬀect of
the administered drugs on these choroidal blood ﬂow
changes was calculated as the interaction between
treatment and time. All statistical analyses were done
using the Statistica software package (Release 4.5,
StatSoft Inc., Tulsa, OK, USA). Data are presented as
means ±SD. A two-tailed p < 0:05 was considered the
level of signiﬁcance.3. Results
Baseline haemodynamic parameters and baseline IOP
on the three study days are presented in Table 1. All
outcome variables were comparable between the three
study days. No adverse events were observed with either
infusion of atropine or propranolol.
As expected a transition from light to dark caused a
decrease in choroidal blood ﬂow and FPA at the pre-
treatment period (Figs. 1 and 2). This decrease was be-
tween 8% and 12% (p < 0:001) for choroidal blood ﬂow
and between 11% and 12% for FPA (p < 0:001). The
change in the outcome parameters was, however, com-
parable on the three study days (choroidal blood ﬂow:
p ¼ 0:73; FPA: p ¼ 0:95). All choroidal outcome pa-
rameters returned to baseline levels when the room light
was switched on again. In contrast to choroidal perfu-
sion parameters neither systolic or diastolic blood
pressure, nor pulse rate or IOP were changed by the
light dark transitions (Table 2).
Atropine and propranolol did not alter choroidal
blood ﬂow parameters during light conditions (Figs. 1
and 2). All choroidal haemodynamic parameters were
within 5% of the pre-treatment value independently of
Fig. 1. Time course of choroidal blood ﬂow (FLOW) during light/dark
transition periods. On each study day one light/dark transition period
was scheduled before drug administration and the second light/dark
transition period was scheduled during infusion of either propranolol
(solid squares), atropine (solid up triangles) or placebo (open circles).
Data are presented as means±SD (n ¼ 15).
Fig. 2. Time course of FPA during light/dark transition periods. On
each study day one light/dark transition period was scheduled before
drug administration and the second light/dark transition period was
scheduled during infusion of either propranolol (solid squares), atro-
pine (solid up triangles) or placebo (open circles). Data are presented
as means±SD (n ¼ 15).
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tered when the room light was switched on. Neither
propranolol (laser Doppler ﬂowmetry: p ¼ 0:61; FPA:
p ¼ 0:73) nor atropine (laser Doppler ﬂowmetry: 0.60;
FPA: p ¼ 0:83) altered blood ﬂow parameters in the
choroid versus placebo. In addition, neither propranolol
nor atropine had an eﬀect on IOP (Table 2). The drugs
were, however, administered at systemically eﬀective
doses. Accordingly, propranolol reduced MAP versus
placebo (p ¼ 0:003), whereas atropine had no eﬀect on
MAP. None of the administered drugs altered PPA(Table 2). Atropine did, however, strongly increase PR
(Table 2), an eﬀect which was highly signiﬁcant versus
placebo (p < 0:001). The reduction in PR in response to
propranolol was also signiﬁcant (p < 0:001).
Light/dark transitions did not aﬀect systemic hae-
modynamic parameters or IOP during either propra-
nolol, atropine, or placebo. In addition, neither atropine
nor propranolol aﬀected the response of choroidal blood
ﬂow parameters versus placebo. Choroidal blood ﬂow
decreased by 9% during the light/dark transition when
propranolol was administered (p ¼ 0:49 versus placebo)
and by 12% when atropine was administered (p ¼ 0:10
versus placebo). The results for FPA were comparable
and this parameters decreased by 12% in response to the
light/dark transition during propranolol infusion
(p ¼ 0:99 versus placebo) and by 10% during atropine
infusion (p ¼ 0:91 versus placebo).4. Discussion
In the present study the hypothesis that the choroidal
blood ﬂow response to a light/dark transition may be
altered by either b-receptor blockade or by muscarinic
receptor blockade was tested in healthy subjects.
Whereas the data of this trial conﬁrm previous reports
from our laboratory (Fuchsj€ager-Mayrl et al., 2001) and
from another group (Longo et al., 2000) that blood ﬂow
reversibly decreases in the dark, none of the pharma-
cological interventions had an eﬀect on this behaviour.
As compared to our previous study an important
methodological diﬀerence has to be considered. In the
present trial the pupil was dilated with tropicamide.
Hence, the light/dark transition in the present study
induced a more pronounced change in retinal luminance
than in our previous study, but the response in choroidal
blood ﬂow parameters was comparable. At present we
do not know which change in terms of retinal irradiance
is required to provoke a change in choroidal blood ﬂow
and a dose/response curve is missing. However, we
deemed it important to standardise pupil diameters,
because of the known eﬀect of atropine on pupil size.
Previous studies clearly indicate that neural mecha-
nisms contribute to the change in choroidal perfusion
during transition from light/dark. In healthy subjects
unilateral light dark conditions lead to a decrease in
choroidal blood ﬂow in both eyes indicating a cross-talk
between both eyes. This is well compatible with previous
studies in pigeons, where the mechanism underlying
changes in choroidal blood ﬂow changes at diﬀerent
retinal illumination levels has been investigated in some
detail (Fitzgerald, Gamlin, Zagvazdin, & Reiner, 1996).
In this species changes in choroidal blood ﬂow evoked
by changes in retinal illumination are largely mediated
via the suprachiasmatic nucleus and the Edinger West-
phal nucleus. One of the lines of evidence supporting
Table 2
Systemic haemodynamic parameters and IOP during the three study days
Min
0 20 40 50 100 120 140 150
Placebo
Mean arterial pressure (mmHg) 84± 9 82± 11 83± 9 82±11 84± 9 85± 8 85± 11 83± 9
Pulse pressure amplitude (mmHg) 58± 10 59± 10 56± 10 61±7 57± 11 59± 10 54± 10 55± 11
Pulse rate (beats/min) 69± 8 69± 10 72± 12 71±10 70± 9 70± 13 71± 10 70± 10
Intraocular pressure (mmHg) 13± 2 13± 2 13± 2 13±2 13± 2 13± 2 13± 2 12± 2
Propranolol
Mean arterial pressure (mmHg) 83± 10 82± 10 85± 8 83±9 81± 8 80± 12 80± 8 76± 8
Pulse pressure amplitude (mmHg) 57± 12 54± 10 55± 14 52±13 52± 14 56± 12 54± 13 52± 14
Pulse rate (beats/min) 71± 10 71± 7 71± 10 65±6 62± 14 66± 17 58± 16 56± 12
Intraocular pressure (mmHg) 14± 2 13± 2 14± 2 13±2 13± 2 12± 2 11± 2 11± 2
Atropine
Mean arterial pressure (mmHg) 84± 9 82± 9 82± 8 83±7 85± 7 83± 7 83± 11 87± 9
Pulse pressure amplitude (mmHg) 56± 9 55± 11 55± 13 55±8 57± 11 54± 11 53± 9 56± 12
Pulse rate (beats/min) 67± 6 69± 5 68± 11 69±9 93± 14 97± 15 97± 17 92± 14
Intraocular pressure (mmHg) 13± 3 12± 2 13± 2 13±2 13± 2 12± 2 11± 2 11± 2
Data are presented as means±SD.
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of the Edinger Westphal nucleus blocked the change in
choroidal blood ﬂow with changing retinal illumination.
Such a control circuit has not yet been shown for any
other species, but several observations clearly indicate
parasympathetic neuronal control of choroidal perfu-
sion. Vasodilatory responses in the mammalian choroid
have been reported in response to nerve stimulation of
the short ciliary nerves from the ciliary ganglion (Bill,
Stjernschantz, & Alm, 1976; Nakanome, Karita, Izumi,
& Tamai, 1995; Stjernschantz, Alm, & Bill, 1976) and of
the facial nerve via its parasympathetic preganglionic
input to the pterygopalatine ganglion (Ruskell, 1971;
Nilsson, Linder, & Bill, 1985; Stjernschantz & Bill,
1980).
Investigation of such phenomena in humans is obvi-
ously diﬃcult. In the present study we chose to modify
the parasympathetic nervous system with the muscarinic
receptor blocker atropine. However, neither the cho-
roidal blood ﬂow response to light/dark transitions nor
basal choroidal blood ﬂow were altered by this inter-
vention, although the drug was administered at sys-
temically eﬀective doses. The latter observation is in
keeping with our previous data, which show that the
choroidal pressure/ﬂow relationship during isometric
exercise is not altered by atropine infusion (Polska et al.,
2003). In a previous study in rabbits the nicotine re-
ceptor antagonist hexamethonium was capable of
changing choroidal blood ﬂow in the choroid (Kiel,
1999). A human study using administration of hexam-
ethonium is, however, ethically not justiﬁed considering
the recently reported adverse event proﬁle of this drug
(McCarthy, 2001).
The second drug studied in the present trial was the
non-selective b-receptor antagonist propranolol modu-
lating the sympathetic nervous system. Previous data onthe role of b-receptors in the control of choroidal blood
ﬂow are inconsistent. Catecholaminergic binding sites
have been observed in the choroid of the cat (Bruninink,
Dawis, Niemeyer, & Lichtensteiger, 1986). A number of
studies investigated the eﬀect of topical b-receptor an-
tagonists used for glaucoma therapy on choroidal per-
fusion parameters in humans (Boles Carenini, Sibour, &
Boles Carenini, 1994; Bosem, Lusky, & Weinreb, 1992;
Schmetterer et al., 1997; Yoshida et al., 1991). Whereas
such data may be important for the clinical management
of glaucoma, they tell little about the pharmacological
relevance of b-receptors in the control of choroidal
blood ﬂow, because their instillation is accompanied by
an increase in ocular perfusion pressure based on their
ocular hypotensive eﬀect. Using very high systemic do-
ses of the b-receptor antagonist timolol Kiel and Patel
(1998) reported a small decrease in basal choroidal
blood ﬂow without any inﬂuence on the choroidal
pressure/ﬂow relationship. In our own previous study
propranolol did neither inﬂuence basal choroidal blood
ﬂow nor did it change the choroidal pressure/ﬂow rela-
tionship during isometric exercise (Polska et al., 2003).
In conclusion, the data of the present study conﬁrm
that light/dark transitions are associated with a decrease
in choroidal blood ﬂow. However, this is neither mod-
ulated by administration of propranolol nor by admin-
istration of atropine. Hence, further studies are required
to elucidate which mechanisms are responsible for this
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